Last reviewed · How we verify
Tafamidis 61 MG
Tafamidis 61 MG is a Small molecule drug developed by University of Texas Southwestern Medical Center. It is currently FDA-approved.
At a glance
| Generic name | Tafamidis 61 MG |
|---|---|
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions (PHASE1)
- A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
- Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation (PHASE4)
- A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults (PHASE1)
- Vyndaqel Capsules Special Investigation (ATTR-CM)
- Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy (PHASE3)
- A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafamidis 61 MG CI brief — competitive landscape report
- Tafamidis 61 MG updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI
Frequently asked questions about Tafamidis 61 MG
What is Tafamidis 61 MG?
Tafamidis 61 MG is a Small molecule drug developed by University of Texas Southwestern Medical Center.
Who makes Tafamidis 61 MG?
Tafamidis 61 MG is developed and marketed by University of Texas Southwestern Medical Center (see full University of Texas Southwestern Medical Center pipeline at /company/university-of-texas-southwestern-medical-center).
What development phase is Tafamidis 61 MG in?
Tafamidis 61 MG is FDA-approved (marketed).
Related
- Manufacturer: University of Texas Southwestern Medical Center — full pipeline
- Compare: Tafamidis 61 MG vs similar drugs
- Pricing: Tafamidis 61 MG cost, discount & access